

Richard M Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5997001/publications.pdf>

Version: 2024-02-01

273
papers

17,307
citations

41344

49
h-index

15732

125
g-index

279
all docs

279
docs citations

279
times ranked

16231
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2022, 36, 210-220.	7.2	12
2	Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. <i>Haematologica</i> , 2022, 107, 836-843.	3.5	14
3	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	5.2	5
4	Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. <i>Haematologica</i> , 2022, 107, 1172-1180.	3.5	21
5	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44
6	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. <i>Leukemia and Lymphoma</i> , 2022, 63, 1934-1941.	1.3	13
7	Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. <i>Experimental Hematology</i> , 2022, 107, 14-19.	0.4	10
8	<i>BCOR</i> and <i>BCORL1</i> Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. <i>Blood Cancer Discovery</i> , 2022, 3, 116-135.	5.0	18
9	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.	1.6	9
10	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	11
11	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	1.4	123
12	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 626-637.	9.4	41
13	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021, 106, 1330-1342.	3.5	19
14	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. <i>Cell Stem Cell</i> , 2021, 28, 514-523.e9.	11.1	130
15	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	29
16	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0249087.	2.5	1
17	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
18	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. <i>Nature Immunology</i> , 2021, 22, 520-529.	14.5	11

#	ARTICLE	IF	CITATIONS
19	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. <i>American Journal of Hematology</i> , 2021, 96, E259-E262.	4.1	1
20	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.	5.2	2
21	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	1.4	91
22	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	1.4	16
23	Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?. <i>Leukemia and Lymphoma</i> , 2021, 62, 3318-3319.	1.3	0
24	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	5.2	16
25	BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 931-932.	3.5	0
26	Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax. <i>Blood</i> , 2021, 138, 4126-4126.	1.4	0
27	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2021, 138, 221-221.	1.4	2
28	Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. <i>Blood</i> , 2021, 138, 2346-2346.	1.4	21
29	Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes. <i>Blood</i> , 2021, 138, 685-685.	1.4	0
30	Medical Simulation in High-Risk AML Improves Clinical Decision Making of Hematologists/Oncologists. <i>Blood</i> , 2021, 138, 4985-4985.	1.4	0
31	Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 2291-2291.	1.4	2
32	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. <i>Blood</i> , 2021, 138, 2642-2642.	1.4	5
33	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. <i>Blood</i> , 2021, 138, 1521-1521.	1.4	4
34	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. <i>Blood</i> , 2021, 138, 2830-2830.	1.4	1
35	A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3728-3728.	1.4	2
36	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27

#	ARTICLE	IF	CITATIONS
37	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). <i>Blood</i> , 2021, 138, 226-226.	1.4	0
38	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). <i>Blood</i> , 2021, 138, 3369-3369.	1.4	0
39	Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. <i>Blood</i> , 2021, 138, 1562-1562.	1.4	0
40	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	3.5	15
41	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 721-729.	3.5	21
42	Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. <i>Leukemia</i> , 2020, 34, 625-629.	7.2	9
43	Optimal therapeutic strategies for mixed phenotype acute leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 95-102.	2.5	19
44	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	4.6	19
45	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
46	Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. <i>Leukemia and Lymphoma</i> , 2020, 61, 2900-2904.	1.3	10
47	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020, 4, 3528-3549.	5.2	113
48	Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. <i>Cancer</i> , 2020, 126, 4735-4743.	4.1	11
49	AML: New Drugs but New Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 341-350.	0.4	23
50	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2968-2980.	3.6	16
51	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2145-2156.	3.6	2
52	Inhibition of the deubiquitinase USP10 induces degradation of SYK. <i>British Journal of Cancer</i> , 2020, 122, 1175-1184.	6.4	19
53	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
54	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. <i>Blood</i> , 2020, 136, 15-17.	1.4	9
56	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 14-15.	1.4	6
57	Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 40-41.	1.4	10
58	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2020, 136, 5-7.	1.4	4
59	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 7-8.	1.4	4
60	Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML. <i>Blood</i> , 2020, 136, 16-17.	1.4	1
61	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
62	Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. <i>Blood</i> , 2020, 136, 10-10.	1.4	0
63	Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies. <i>Blood</i> , 2020, 136, 38-39.	1.4	12
64	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 247-254.	3.7	55
65	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019, 134, 867-879.	1.4	55
66	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. <i>British Journal of Haematology</i> , 2019, 187, 488-501.	2.5	30
67	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. <i>Cancer</i> , 2019, 125, 3845-3852.	4.1	10
68	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986064.	2.5	90
69	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	27.0	545
70	High <i>NPM1</i> mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 921-928.	4.1	24
71	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	5.5	25
72	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. <i>Leukemia</i> , 2019, 33, 2393-2402.	7.2	44

#	ARTICLE	IF	CITATIONS
73	Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. <i>Leukemia Research Reports</i> , 2019, 12, 100189.	0.4	2
74	Single 6-mg dose of rasburicase: The experience in a large academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1349-1356.	0.9	6
75	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , 2019, 7, 100-112.	3.4	220
76	Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 3908-3908.	1.4	7
77	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	1.4	29
78	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	1.4	30
79	The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment. <i>Blood</i> , 2019, 134, 2681-2681.	1.4	1
80	Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 3829-3829.	1.4	10
81	Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions. <i>Blood</i> , 2019, 134, 1326-1326.	1.4	13
82	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. <i>Blood</i> , 2019, 134, 3832-3832.	1.4	0
83	Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols. <i>Blood</i> , 2019, 134, 182-182.	1.4	0
84	Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. <i>Blood</i> , 2019, 134, 1442-1442.	1.4	0
85	Exploiting an Asp-Glu α -switch in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	69
86	Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. <i>JAMA Oncology</i> , 2018, 4, 686.	7.1	83
87	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	299
88	A concise review of BCL-2 inhibition in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 145-154.	2.2	24
89	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	1.4	64
90	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	1.6	682

#	ARTICLE	IF	CITATIONS
91	Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. <i>Haematologica</i> , 2018, 103, 1758-1759.	3.5	5
92	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
93	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. <i>Cancer</i> , 2018, 124, 4601-4609.	4.1	8
94	What FLT3 inhibitor holds the greatest promise?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 401-404.	1.7	11
95	The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. <i>Gynecologic Oncology</i> , 2018, 151, 187-189.	1.4	4
96	Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. <i>Cancer Cell</i> , 2018, 34, 355-357.	16.8	5
97	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 444-453.	5.2	115
98	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
99	Integrative omics to detect bacteremia in patients with febrile neutropenia. <i>PLoS ONE</i> , 2018, 13, e0197049.	2.5	10
100	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 877-882.	1.7	95
101	Application of multi-state models in cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 489-498.	1.6	36
102	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	7.2	33
103	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E49-E52.	4.1	14
104	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	1.4	9
105	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. <i>Blood</i> , 2018, 132, 1446-1446.	1.4	2
106	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. <i>Blood</i> , 2018, 132, 1491-1491.	1.4	0
107	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017, 129, 1763-1767.	1.4	78
108	3 + 7 + FLT3 inhibitors: 1 + 1 % 2. <i>Blood</i> , 2017, 129, 1061-1062.	1.4	4

#	ARTICLE	IF	CITATIONS
109	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313.	30.7	79
110	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 3175-3183.	1.4	126
111	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
112	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
113	The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 663-680.	2.2	30
114	Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. <i>Current Opinion in Hematology</i> , 2017, 24, 139-145.	2.5	44
115	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 3165-3174.	1.4	114
116	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
117	Inhibition of USP10 induces degradation of oncogenic FLT3. <i>Nature Chemical Biology</i> , 2017, 13, 1207-1215.	8.0	89
118	Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 312-316.	1.7	15
119	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 86-91.	2.5	29
120	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , 2017, 8, 67639-67650.	1.8	26
121	Novel Therapeutics in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 495-503.	3.8	12
122	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1786-1789.	5.2	13
123	Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?. <i>Journal of Oncology Practice</i> , 2017, 13, 471-480.	2.5	15
124	Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2017, 130, 639-639.	1.4	26
125	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML. <i>Journal of Clinical Oncology</i> , 2017, 35, 7016-7016.	1.6	4
126	A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 7503-7503.	1.6	1

#	ARTICLE	IF	CITATIONS
127	A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).. Journal of Clinical Oncology, 2017, 35, TPS7074-TPS7074.	1.6	2
128	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 2017, 8, 52026-52044.	1.8	19
129	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget, 2017, 8, 109973-109984.	1.8	19
130	Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.. Journal of Clinical Oncology, 2017, 35, 7004-7004.	1.6	0
131	Prevalence and complications associated with off-label use of lenalidomide in older patients with myelodysplastic syndromes (MDS).. Journal of Clinical Oncology, 2017, 35, 7054-7054.	1.6	0
132	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget, 2016, 7, 29131-29142.	1.8	21
133	Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. British Journal of Haematology, 2016, 173, 713-721.	2.5	7
134	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four <sc>CALGB</sc> (alliance) clinical trials. American Journal of Hematology, 2016, 91, 199-204.	4.1	44
135	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799.	4.1	14
136	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Science Translational Medicine, 2016, 8, 368ra171.	12.4	140
137	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1977-1979.	1.3	2
138	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematology, the, 2016, 3, e276-e283.	4.6	19
139	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
140	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery, 2016, 6, 1106-1117.	9.4	799
141	Targeting MTHFD2 in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 1285-1306.	8.5	118
142	Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea. Biology of Blood and Marrow Transplantation, 2016, 22, 971-972.	2.0	4
143	Clinical impact of <i>ABL1</i> kinase domain mutations and <i>IKZF1</i> deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia and Lymphoma, 2016, 57, 2298-2306.	1.3	45
144	Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 476-481.	2.8	17

#	ARTICLE	IF	CITATIONS
145	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. <i>Blood</i> , 2016, 128, 1070-1070.	1.4	28
146	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1071-1071.	1.4	47
147	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	1.4	5
148	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). <i>Blood</i> , 2016, 128, 1638-1638.	1.4	2
149	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 214-214.	1.4	1
150	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). <i>Blood</i> , 2016, 128, 215-215.	1.4	25
151	Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR). <i>Blood</i> , 2016, 128, 2859-2859.	1.4	7
152	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 343-343.	1.4	44
153	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. <i>Blood</i> , 2016, 128, 4045-4045.	1.4	1
154	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , 2016, 128, 4052-4052.	1.4	32
155	Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. <i>Blood</i> , 2016, 128, 633-633.	1.4	1
156	Measurement and Prevalence of Cognitive Impairment in Older Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 689-689.	1.4	1
157	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901.	1.4	42
158	Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. <i>Blood</i> , 2016, 128, 902-902.	1.4	15
159	Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. <i>Blood</i> , 2016, 128, 906-906.	1.4	16
160	Simultaneous inhibition of Vps34 kinase would enhance PI3K γ inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016, 7, 53515-53525.	1.8	19
161	Characterization of selective and potent PI3K γ inhibitor (PI3KD-IN-015) for B-Cell malignancies. <i>Oncotarget</i> , 2016, 7, 32641-32651.	1.8	7
162	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 38974-38987.	1.8	36

#	ARTICLE	IF	CITATIONS
163	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 919-919.	1.4	0
164	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥ 75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. <i>Blood</i> , 2016, 128, 2818-2818.	1.4	1
165	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1681-1681.	1.4	0
166	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). <i>Blood</i> , 2016, 128, 287-287.	1.4	0
167	Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 523-523.	1.4	0
168	CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). <i>Blood</i> , 2016, 128, 2740-2740.	1.4	0
169	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. <i>Blood</i> , 2016, 128, 524-524.	1.4	0
170	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.	1.4	747
171	Refractory myeloid sarcoma with a FIP1L1-PDGFR α rearrangement detected by clinical high throughput somatic sequencing. <i>Experimental Hematology and Oncology</i> , 2015, 4, 30.	5.0	6
172	Health care utilization and end-of-life care for older patients with acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2840-2848.	4.1	113
173	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , 2015, 28, 965-976.	5.5	31
174	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. <i>Journal of Geriatric Oncology</i> , 2015, 6, 288-298.	1.0	29
175	New Models of Therapy: When Acute Leukemia Becomes Chronic. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1856-1857.	2.0	0
176	Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 204-210.	0.8	13
177	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 29-41.	16.8	95
178	How I treat mixed-phenotype acute leukemia. <i>Blood</i> , 2015, 125, 2477-2485.	1.4	126
179	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1252-1257.	1.6	57
180	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2249-2259.	4.1	53

#	ARTICLE	IF	CITATIONS
181	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	1.6	149
182	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1299-1308.	0.8	15
183	Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 4262-4269.	7.0	20
184	Should older adults with AML receive post-remission therapy?. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 106-111.	1.7	3
185	Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. <i>Blood</i> , 2015, 126, 1306-1306.	1.4	36
186	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. <i>Blood</i> , 2015, 126, 2104-2104.	1.4	2
187	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. <i>Blood</i> , 2015, 126, 2549-2549.	1.4	5
188	Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). <i>Blood</i> , 2015, 126, 258-258.	1.4	13
189	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	1.4	6
190	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). <i>Blood</i> , 2015, 126, 319-319.	1.4	18
191	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.	1.4	57
192	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015, 126, 3252-3252.	1.4	2
193	Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study. <i>Blood</i> , 2015, 126, 3306-3306.	1.4	2
194	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. <i>Blood</i> , 2015, 126, 449-449.	1.4	3
195	The Multi-Kinase inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	1.4	104
196	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. <i>Blood</i> , 2015, 126, 80-80.	1.4	38
197	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. <i>Blood</i> , 2015, 126, 864-864.	1.4	7
198	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015, 126, 908-908.	1.4	17

#	ARTICLE	IF	CITATIONS
199	Targeting MTHFD2 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 443-443.	1.4	2
200	Identification of CKMT1B As a New Target in EVI1-Positive AML. <i>Blood</i> , 2015, 126, 3674-3674.	1.4	0
201	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. <i>Blood</i> , 2015, 126, 2126-2126.	1.4	0
202	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2550-2550.	1.4	0
203	Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML. <i>Blood</i> , 2015, 126, 870-870.	1.4	0
204	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 88-88.	1.4	0
205	Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML. <i>Blood</i> , 2015, 126, 326-326.	1.4	0
206	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 1138-1138.	1.4	4
207	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , 2015, 126, 1304-1304.	1.4	0
208	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3310-3310.	1.4	0
209	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. <i>Leukemia</i> , 2014, 28, 1754-1758.	7.2	24
210	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
211	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 226-242.	16.8	126
212	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 430-434.	0.8	23
213	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	1.4	486
214	ÅSelective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. <i>Blood</i> , 2014, 124, 995-995.	1.4	0
215	Acute Myeloid Leukemia in First Remission: To Choose Transplantation or Not?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1262-1266.	1.6	26
216	Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells. <i>Blood</i> , 2013, 122, 1479-1479.	1.4	2

#	ARTICLE	IF	CITATIONS
217	BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 238-238.	1.4	2
218	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013, 122, 2823-2823.	1.4	15
219	Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. <i>Blood</i> , 2013, 122, 1378-1378.	1.4	0
220	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2013, 122, 2540-2540.	1.4	0
221	Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors. <i>Blood</i> , 2013, 122, 3749-3749.	1.4	3
222	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 984-1021.	4.9	236
223	Is it time to revisit standard post-remission therapy?. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 437-441.	1.7	8
224	The Clinical Role of Micrnas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). <i>Blood</i> , 2012, 120, 1387-1387.	1.4	1
225	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. <i>Blood</i> , 2012, 120, 230-230.	1.4	14
226	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	1.4	3
227	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012, 120, 44-44.	1.4	4
228	SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 773-773.	1.4	1
229	Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Is Associated with Altered Expression of Splicing Factors. <i>Blood</i> , 2012, 120, 652-652.	1.4	0
230	Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System. <i>Blood</i> , 2012, 120, 4933-4933.	1.4	0
231	Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance). <i>Blood</i> , 2012, 120, 1293-1293.	1.4	0
232	Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 509-514.	1.7	7
233	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
234	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011, 118, 258-258.	1.4	7

#	ARTICLE	IF	CITATIONS
235	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. <i>Blood</i> , 2011, 118, 2622-2622.	1.4	8
236	Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Identifies Potential Novel Targets. <i>Blood</i> , 2011, 118, 761-761.	1.4	0
237	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. <i>Blood</i> , 2011, 118, 1442-1442.	1.4	0
238	Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. <i>Journal of Clinical Oncology</i> , 2010, 28, 4339-4345.	1.6	442
239	New agents in post-remission therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 475-479.	1.7	1
240	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. <i>Blood</i> , 2010, 116, 848-848.	1.4	1
241	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3 β (GSK-3 β) as a Modulator of Differentiation In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 1000-1000.	1.4	0
242	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349.	7.4	758
243	Prognostic factors in AML in relation to (ab)normal karyotype. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 523-528.	1.7	20
244	How I treat patients with myelodysplastic syndromes. <i>Blood</i> , 2009, 113, 6296-6303.	1.4	82
245	Identification of Novel Splice Variants of Multiple Genes Using Genome-Wide Analysis of Alternative Splicing in Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 1278-1278.	1.4	2
246	A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3.. <i>Blood</i> , 2009, 114, 634-634.	1.4	14
247	A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.. <i>Blood</i> , 2009, 114, 755-755.	1.4	23
248	Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. <i>American Journal of Hematology</i> , 2008, 83, 771-777.	4.1	18
249	Timed sequential induction chemotherapy in AML: Time for reflection. <i>American Journal of Hematology</i> , 2008, 83, 829-830.	4.1	2
250	Are new agents really making a difference in MDS?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 639-646.	1.7	0
251	Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 1-15.	0.3	12
252	Novel therapeutic agents in acute myeloid leukemia. <i>Experimental Hematology</i> , 2007, 35, 163-166.	0.4	23

#	ARTICLE	IF	CITATIONS
253	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 587-587.	1.4	47
254	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. Blood, 2007, 110, 886-886.	1.4	3
255	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 2006, 108, 3477-3483.	1.4	194
256	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61.. Blood, 2006, 108, 157-157.	1.4	16
257	Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 158-158.	1.4	12
258	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 1858-1858.	1.4	4
259	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. Blood, 2006, 108, 259-259.	1.4	1
260	An Erythroid Differentiation Gene Expression Signature Predicts Response to Lenalidomide in Myelodysplasia.. Blood, 2006, 108, 2668-2668.	1.4	1
261	Monitoring Imatinib Resistance with a α -Polony α -Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).. Blood, 2006, 108, 837-837.	1.4	1
262	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias.. Blood, 2006, 108, 1405-1405.	1.4	0
263	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105, 54-60.	1.4	632
264	Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.. Blood, 2005, 106, 404-404.	1.4	31
265	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788.	1.4	0
266	Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.. Blood, 2004, 104, 1792-1792.	1.4	25
267	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. Blood, 2004, 104, 873-873.	1.4	5
268	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
269	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
270	Treatment of acute myeloid leukemia: State-of-the-art and future directions. Seminars in Hematology, 2002, 39, 4-10.	3.4	28

#	ARTICLE	IF	CITATIONS
271	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	1.6	180
272	Molecular Characterization of the t(8; 13)(p11;q12) Translocation Associated With an Atypical Myeloproliferative Disorder: Evidence for Three Discrete Loci Involved in Myeloid Leukemias on 8p11. <i>Blood</i> , 1997, 90, 3136-3141.	1.4	47
273	Inhibition of protein kinase C is associated with a decrease in myc expression in human myeloid leukemia cells. <i>FEBS Letters</i> , 1991, 294, 73-76.	2.8	13